Jeff Jones
Stock Analyst at Oppenheimer
(3.36)
# 958
Out of 5,182 analysts
93
Total ratings
27.06%
Success rate
10.22%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Maintains: Outperform | $50 → $55 | $23.37 | +135.34% | 4 | Mar 30, 2026 | |
| PTHS Pelthos Therapeutics | Maintains: Outperform | $60 → $62 | $20.40 | +203.92% | 4 | Mar 20, 2026 | |
| PHAR Pharming Group | Reiterates: Outperform | $42 → $41 | $16.09 | +154.82% | 1 | Mar 13, 2026 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $32 → $33 | $14.69 | +124.64% | 7 | Mar 13, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $53 → $57 | $10.17 | +460.47% | 11 | Mar 10, 2026 | |
| AVBP ArriVent BioPharma | Reiterates: Outperform | $44 → $50 | $24.89 | +100.88% | 4 | Mar 6, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $67 → $120 | $85.40 | +40.52% | 7 | Dec 9, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $1.58 | +1,482.28% | 9 | Aug 27, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $6.03 | +181.92% | 4 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $30.83 | +178.95% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $2.25 | +700.00% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.55 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $4.41 | +262.81% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.35 | +3,233.33% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $9.27 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $3.27 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.96 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.34 | +1,019.40% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,875 | $2.32 | +80,718.97% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $3.78 | +29,000.53% | 2 | Nov 17, 2022 |
Alumis
Mar 30, 2026
Maintains: Outperform
Price Target: $50 → $55
Current: $23.37
Upside: +135.34%
Pelthos Therapeutics
Mar 20, 2026
Maintains: Outperform
Price Target: $60 → $62
Current: $20.40
Upside: +203.92%
Pharming Group
Mar 13, 2026
Reiterates: Outperform
Price Target: $42 → $41
Current: $16.09
Upside: +154.82%
Corvus Pharmaceuticals
Mar 13, 2026
Reiterates: Outperform
Price Target: $32 → $33
Current: $14.69
Upside: +124.64%
Corbus Pharmaceuticals Holdings
Mar 10, 2026
Maintains: Outperform
Price Target: $53 → $57
Current: $10.17
Upside: +460.47%
ArriVent BioPharma
Mar 6, 2026
Reiterates: Outperform
Price Target: $44 → $50
Current: $24.89
Upside: +100.88%
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $67 → $120
Current: $85.40
Upside: +40.52%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $1.58
Upside: +1,482.28%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $6.03
Upside: +181.92%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $30.83
Upside: +178.95%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $2.25
Upside: +700.00%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $2.55
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $4.41
Upside: +262.81%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.35
Upside: +3,233.33%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $9.27
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $3.27
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $2.96
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.34
Upside: +1,019.40%
Mar 24, 2023
Reiterates: Outperform
Price Target: $1,875
Current: $2.32
Upside: +80,718.97%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $3.78
Upside: +29,000.53%